Evaluation of safety and efficacy of Jadwar plant in improving the withdrawal symptoms of opioids

Evaluation of safety and efficacy of jadwar plant in improving the withdrawal symptoms of opioids: A triple blind trial Study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170112031893N7

Enrollment

Registered

2020-06-18

Start date

2020-08-22

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mental and behavioural disorders due to use of opioids. Opioid related disorders

Interventions

Intervention 1: Intervention group: Patients receiving 500 mg capsules of Jadwar plant powder produced by Shefangar Company three times daily for three months. Intervention 2: Control group: Patients

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients were abusing opioids for at least 1 year All patients were at the beginning of induction phase of Methadone maintenance treatment protocol Subjects should not recieve any other medication which affects withdrawal symptoms

Exclusion criteria

Exclusion criteria: Any allergies to the active ingredient of the drug or side effects Getting Cancer

Design outcomes

Primary

Measure	Time frame
Opiate withdrawal syndrome score. Timepoint: Baseline, 4,8 and12 weeks after starting the medication. Method of measurement: Opiate withdrawal syndrome questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Yusefi

Ghoum University of Medical Sciences

driran1390@yahoo.com+98 25 3886 0146

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026